-
1 Comment
Coloplast A/S is currently in a long term uptrend where the price is trading 13.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 11.0.
Coloplast A/S's total revenue rose by 0.6% to $5B since the same quarter in the previous year.
Its net income has increased by 4.0% to $1B since the same quarter in the previous year.
Finally, its free cash flow grew by 18.6% to $957M since the same quarter in the previous year.
Based on the above factors, Coloplast A/S gets an overall score of 5/5.
Sector | Healthcare |
---|---|
Industry | Medical Instruments & Supplies |
Exchange | F |
CurrencyCode | EUR |
ISIN | DK0060448595 |
Beta | 0.6 |
---|---|
Market Cap | 22B |
PE Ratio | 32.86 |
Target Price | 19.05 |
Dividend Yield | 3.1% |
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CBHD.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025